The 14.9% is a real number and a bad promise. Semaglutide for weight loss produced that average in the FDA’s own weight-management trial, and the same label shows a group of patients at 9.6% and another at 16%. One of those three numbers lands in the advertisement, and it is rarely the one that applies to the person reading it. Semaglutide for weight loss averages about 15% of body weight over 68 weeks in the FDA-approved label, and the label’s own trials run from 9.6% in adults with type 2 diabetes to 16% in adults who also received an intensive diet and exercise program.
The label that carries those numbers is the reason this site exists. Anyone can quote the average. The table behind it is where your expectation gets set, and it is public.
Semaglutide for Weight Loss – The Label’s Table Beats the Headline
Wegovy is the brand name for semaglutide when the purpose is weight reduction rather than blood sugar, and the dose studied in the main trial was 2.4 mg injected once a week for 68 weeks. That trial enrolled 1,961 adults with a body mass index of 30 or higher, or a BMI of 27 to 29.9 plus at least one weight-related condition. Patients with type 2 diabetes were excluded.
The average participant lost 14.9% of body weight; the placebo group lost 2.4%. Behind that average, the label reports how many people crossed each threshold, and those numbers help a patient more than the mean:
- 83.5% of the treated group lost at least 5% of body weight, against 31.1% on placebo
- 66.1% lost at least 10%, against 12%
- 47.9% lost at least 15%, against 4.8%
- 30.2% lost at least 20%, against 1.7%
Two more trials sit in the same section of the label, and they bracket the range. Among 807 adults with type 2 diabetes and a BMI of 27 or higher, the average loss was 9.6% against 3.4% on placebo. Among 611 adults who received an eight-week low-calorie diet followed by a supervised diet and exercise program, the average loss was 16% against 5.7%.
Put a face on it. The mean participant in the largest trial was a 46-year-old woman weighing 105.3 kg. At 14.9% she finishes about 15.7 kg lighter. Her counterpart in the diabetes trial starts at 99.8 kg and finishes about 9.6 kg lighter on the identical weekly schedule. Same molecule, six points apart, and the difference walked in the door with the patient.
The 7.2 mg Ceiling – The Strongest Dose Is Not the Advertised One
The dose ladder in the label runs 0.25 mg for four weeks, then 0.5 mg, 1 mg and 1.7 mg at four-week steps, with a maintenance dose of 2.4 mg from week 17. A later paragraph adds a ceiling most patients have not been told about: an adult who tolerates 2.4 mg for at least four weeks and needs more weight reduction may move to a maximum of 7.2 mg once weekly. The pen exists as a 7.2 mg single dose under a separate name.
The trials behind it are worth reading before anyone asks for the top dose. In a 72-week study of 1,407 adults with obesity and no diabetes, the average loss was 18.8% at 7.2 mg, 15.5% at 2.4 mg and 3.9% on placebo. Nearly half the 7.2 mg group, 45.5%, lost at least 20% of body weight, against 32.3% at 2.4 mg. A second 72-week trial in 512 adults with obesity plus type 2 diabetes produced 13.2% at 7.2 mg against 10.4% at 2.4 mg.
The extra three points of weight loss arrive with a receipt. In the same studies, the label reports nausea in 39% of patients at 7.2 mg, 35% at 2.4 mg and 13% on placebo. Vomiting ran 22%, 16% and 6%. Constipation ran 20%, 19% and 8%. Dysesthesia, the label’s term for tingling, burning or numb skin, ran 22% at the top dose, 6% at 2.4 mg and zero on placebo. Hair loss ran 6%, 3% and 1%.
The strongest dose is not a secret and not a scam. It is a trade with written terms, and the terms include a nerve-skin complaint that more than tripled. The full side-effect table for that top dose gets its own reading on the Wegovy side-effects page here.
Study 5 – The Regain Waits on the Other Side
One trial in the label answers the question patients ask on the first day. Investigators enrolled 902 adults, escalated all of them to 2.4 mg over 20 weeks, then randomized 803 of them to continue the drug or switch to a placebo for the next 48 weeks. The mean weight fell from 106.8 kg at enrollment to roughly 96 kg by the point of randomization.
From there the groups separated in opposite directions. The patients who continued lost another 7.9%. The patients switched to placebo regained 6.9%. The gap between them at week 68 was 14.8 percentage points.
That table is the strongest argument for treating obesity as a chronic condition rather than a project with an end date. The drug holds a lower weight while it stays in the body. Take it away and the body negotiates the weight back.
The Eligibility Line – BMI 30, or 27 With a Condition
The FDA-approved indication names three groups. The injection reduces excess body weight and maintains the reduction long term in adults with obesity, in adolescents aged 12 and older with obesity, and in adults with overweight who have at least one weight-related condition. The trials translate that into BMI 30 or higher, or BMI 27 to 29.9 with a comorbidity such as high blood pressure or abnormal cholesterol.
The same section adds a limitation of use worth printing on a refrigerator: pairing a semaglutide product with another semaglutide product or with any other GLP-1 receptor agonist does not have a recommended use. Stacking shots from two prescriptions doubles a dose rather than improving it.
Two further indications sit in the label. In adults with established cardiovascular disease plus obesity or overweight, the drug reduces the risk of a major cardiovascular event, a finding from a trial of 17,604 patients followed for a median of 41.8 months. In adults with noncirrhotic MASH and moderate to advanced liver fibrosis, the drug carries an accelerated approval that expects a confirmatory trial.
Semaglutide for Weight Loss in Adolescents – A Different Number for a Different Measure
The adolescent trial enrolled 201 patients aged 12 and older whose BMI sat at or above the 95th percentile for age and sex. The primary endpoint was change in BMI rather than body weight, and the treated group improved by 16.1% while the placebo group moved up by 0.6%. About 77% of the treated adolescents recorded at least a 5% reduction in BMI, against 19.7% on placebo.
That 16.1% is not comparable to the adult 14.9%. A change in BMI and a change in body weight are different measurements, so quoting them side by side misleads whoever reads them in the wrong order.
The label adds one warning that adult readers should not borrow as reassurance. Cholelithiasis and cholecystitis, gallstones and gallbladder inflammation, showed up more often in adolescent patients aged 12 and older than in adults on the same drug.
Compounded Semaglutide – Not the Drug in Any of These Trials
Everything above describes an FDA-approved product measured in trials run to a regulatory standard. Compounded semaglutide is a different regulatory animal, and the difference is not a technicality.
The FDA states the position in plain language: compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed. Its advisory page for compounded GLP-1 products reports the counts it has collected as of 31 May 2026, and they moved: 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. The same page notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events, so the real number sits above the printed one.
Three more items from that page matter at home. Multi-dose vials of sterile medication should be discarded within 28 days of first use even if liquid remains, and the agency says not to follow a compounder’s instructions that stretch that window. Salt forms of the drug, semaglutide sodium and semaglutide acetate, are different active ingredients from the one in the approved products, and the agency says they should not be used to compound semaglutide. Retatrutide and cagrilintide cannot be used in compounding at all.
The regulatory ground shifted again on 30 April 2026, when the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances. “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary. Comments closed on 29 June 2026 and a final determination is pending, so the pathway is not settled.
None of that makes a pharmacy a bad actor. It does mean the vial in the refrigerator carries a shorter paper trail, a shallower safety review and a label the agency did not approve, and a patient deserves to know which product they hold.
The Missed Dose – Two Days, Not Five
Two pens holding the same molecule draw the line in different places, and the label on your box decides which rule applies to you.
Wegovy frames the missed dose by distance to the next one. If the next scheduled dose sits more than two days away, take the missed dose as soon as possible. If it sits less than two days away, skip it and resume on the regular day. Two or more consecutive missed doses mean restarting the escalation ladder at a lower dose rather than jumping back to the maintenance level.
Ozempic frames the same problem as a five-day window: take the missed dose within five days, or skip it if more than five days have passed. The two labels also part company on the ceiling, 2.4 mg against 2 mg, and on the purpose, weight reduction against blood sugar. Those details are separate from how each drug works and closer to how a patient’s month goes, which is why the Ozempic dosage page here walks through the pen side of that question.
Frequently asked questions
How much weight do people lose on semaglutide for weight loss?
In the label’s largest weight-management trial, adults lost an average of 14.9% of body weight over 68 weeks against 2.4% on placebo. Across the label’s trials the range runs from 9.6% in adults with type 2 diabetes to 16% with intensive diet and exercise support.
What is the highest dose of semaglutide for weight loss?
The recommended maintenance dose is 2.4 mg once weekly. The label allows an increase to a maximum of 7.2 mg once weekly for adults who tolerate 2.4 mg for at least four weeks and need further weight reduction. That dose produced 18.8% average weight loss over 72 weeks against 15.5% at 2.4 mg.
What happens when you stop taking semaglutide for weight loss?
The withdrawal trial in the label randomized 803 adults who had already reached 2.4 mg. Those who continued lost another 7.9% of body weight, while those switched to placebo regained 6.9%, a gap of 14.8 percentage points over 48 weeks.
Who qualifies for semaglutide for weight loss?
Adults with a BMI of 30 or higher, or a BMI of 27 to 29.9 with at least one weight-related condition such as high blood pressure or abnormal cholesterol. Adolescents aged 12 and older qualify at a BMI at or above the 95th percentile for age and sex.
Is compounded semaglutide the same as the Wegovy in these trials?
No. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before marketing. The trials behind the 14.9% studied the approved product.
How long does the 0.25 mg starting dose take to work?
The 0.25 mg dose is a tolerance step that runs for four weeks, and the label does not present it as a treatment dose. The 2.4 mg maintenance dose arrives at week 17.
Can you take Wegovy and Ozempic at the same time?
No. The label’s limitation of use says pairing a semaglutide product with another semaglutide product or with any other GLP-1 receptor agonist does not have a recommended use. The two pens hold the same molecule.
Sources: DailyMed, WEGOVY (semaglutide) injection, prescribing information, retrieved 16 October 2026; FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, retrieved 16 October 2026; FDA news release, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, 30 April 2026; trial registrations NCT03548935, NCT03548987, NCT05646706, NCT05649137 and NCT04102189.
Two disclosures: compounded semaglutide is not an FDA-approved drug and the FDA does not review it for safety, effectiveness or quality; and this site is a directory for patients looking for licensed care, not a medical practice. Dosing decisions belong to a prescriber who has examined you.